<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04115774</url>
  </required_header>
  <id_info>
    <org_study_id>21632/2013</org_study_id>
    <nct_id>NCT04115774</nct_id>
  </id_info>
  <brief_title>Registry of Osteogenesis Imperfecta</brief_title>
  <acronym>ROI</acronym>
  <official_title>Registry of Osteogenesis Imperfecta That Collects Clinical, Functional, Genetic, Genealogical, Imaging, Surgical, Quality of Life Data. Data Are Linked to Patients Biological Sample</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luca Sangiorgi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ROI is a retrospective and prospective registry, finalized to care and research. It is
      articulated in main sections - strongly related and mutually dependent on each other -
      corresponding to different data domains: personal information, clinical data, genetic data,
      genealogical data, surgeries, etc. This approach has been individuated in order to
      corroborate and integrate data from different resources and aspects of the diseases and to
      correlate genetic background and phenotypic outcomes, in order to better investigate diseases
      pathophysiology.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The common way to collect patient information is frequently chaotic and inconvenient
      (sometimes even unsafe), particularly when dealing with rare diseases. The need to simplify
      the diagnostic process and to overcome the difficulties of data storage and analysis,
      suggested in 2013 to implement the Registry of Osteogenesis Imperfecta (ROI).

      The ROI relies on an IT Platform named Genotype-phenotype Data Integration platform
      -GeDI.This solution, realized by a collaboration among Medical Genetic Department and a local
      software-house (NSI - Nier IT Solution), is a General Data Protection Regulation
      (GDPR)-compliant, multi-client, web-accessible system and it has been designed according to
      current medical informatics standards (Orphanet code, ICD-10, Human Genome Variants Society,
      Findability Accessibility Interoperability Reusability Principles). GeDI is continuously
      implemented to improve management of persons with Osteogenesis Imperfecta and to help
      researchers in analysing collected information. ROI is articulated in main sections:

        1. Personal data: it comprises general information, birth details and residence data

        2. Patient data: including the patients internal code, the hospital code and other details
           on patients

        3. Diagnosis: the diagnosis, the status (affected, suspect, etc.), age at diagnosis,
           comorbidities, allergies, etc.

        4. Genogram: a tool to design family transmission of the disease, flanked by info on
           diseases status of all included relatives

        5. Clinical events: records 23 signs and symptoms of Osteogenesis Imperfecta (representing
           the main Osteogenesis Imperfecta features) and 12 additional items to describe the
           disease

        6. Genetic Analysis and Alteration: including technique, sample information, duration of
           analysis, etc. In addition, this section comprises detailed information on detected
           pathological variants (gene, international reference, DNA change, Protein change,
           genomic position, etc.)

        7. Visits: it includes the typology of the visit (genetic, orthopaedic, rehabilitation,
           paediatric, etc.), the date of the visit, treatment, prescription, imaging, etc.

        8. Surgeries: this section contains information on the surgeries type, the age of the
           patients, the site/localization of the procedures, etc.

        9. Documents: this repository is allowed to store all type of documents (radiological
           reports, imaging, consents, clinical reports, etc.)

       10. Consents: this section comprises a complete overview of all collected consents,
           including the date of collection.

       11. Samples: it comprises the type of samples (DNA, tissue, whole peripheral blood, etc.)
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 28, 2013</start_date>
  <completion_date type="Anticipated">February 29, 2032</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>Natural History and Epidemiology</measure>
    <time_frame>25 years</time_frame>
    <description>To maintain an established registry in order to assess epidemiology and natural history (such as incidence, prevalence, etc.). Collection of physical examinations (severity of the disease), orthopaedics and functionals data (number of fractures, fracture sites, deafness, etc.), genetics background (target gene, type of mutation, etc.) and family history (inheritance in maternal or paternal line, etc.).
Clinical, orthopaedic and functional features are updated at each follow up. Clinical reports, medical charts and imaging are the primary source of data.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genotype-Phenotype Correlation</measure>
    <time_frame>25 years</time_frame>
    <description>The secondary outcome comprises the correlation between genotype and phenotype. This includes, but is not limited to clinical features and genetic background. This will be pursued using the information collected during visits and follow-ups and the genetic information resulting from molecular investigations.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Disease evolution</measure>
    <time_frame>25 years</time_frame>
    <description>This outcome aims to investigate the evolution of Osteogenesis Imperfecta during time. This will be evaluated within the families and among the families.
Main clinical features, such as height, number of fractures, bone evaluations, will be collected both retrospectively and prospectively. An evaluation of these parameters will be performed at each visit to keep trace on the progression of the clinical manifestations.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Osteogenesis Imperfecta patients</arm_group_label>
    <description>The group comprises all patients affected by Osteogenesis Imperfecta, including prenatal and fetal diagnosis of Osteogenesis Imperfecta</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bisphosphonates</intervention_name>
    <description>Since this is an observational study, the investigators collect general information on bisphosphonates treatment/impact</description>
    <arm_group_label>Osteogenesis Imperfecta patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole peripheral blood, DNA, lymphocytes
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients affected by Osteogenesis Imperfecta. The Registry will include also data on
        foetuses (prenatal and abortion).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All Osteogenesis Imperfecta patients, including prenatal and fetal diagnosis of
             Osteogenesis Imperfecta

        Exclusion Criteria:

          -  Any condition unrelated to Osteogenesis Imperfecta
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Sangiorgi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Ortopedico Rizzoli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Irccs Istituto Ortopedico Rizzoli</name>
      <address>
        <city>Bologna</city>
        <state>Emilia Romagna</state>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Ablin DS, Sane SM. Non-accidental injury: confusion with temporary brittle bone disease and mild osteogenesis imperfecta. Pediatr Radiol. 1997 Feb;27(2):111-3. Review.</citation>
    <PMID>9028840</PMID>
  </reference>
  <reference>
    <citation>Davie MW, Haddaway MJ. Bone mineral content and density in healthy subjects and in osteogenesis imperfecta. Arch Dis Child. 1994 Apr;70(4):331-4.</citation>
    <PMID>8185368</PMID>
  </reference>
  <reference>
    <citation>Chapman S, Hall CM. Non-accidental injury or brittle bones. Pediatr Radiol. 1997 Feb;27(2):106-10. Review.</citation>
    <PMID>9028839</PMID>
  </reference>
  <reference>
    <citation>Lindert U, Cabral WA, Ausavarat S, Tongkobpetch S, Ludin K, Barnes AM, Yeetong P, Weis M, Krabichler B, Srichomthong C, Makareeva EN, Janecke AR, Leikin S, Röthlisberger B, Rohrbach M, Kennerknecht I, Eyre DR, Suphapeetiporn K, Giunta C, Marini JC, Shotelersuk V. MBTPS2 mutations cause defective regulated intramembrane proteolysis in X-linked osteogenesis imperfecta. Nat Commun. 2016 Jul 6;7:11920. doi: 10.1038/ncomms11920.</citation>
    <PMID>27380894</PMID>
  </reference>
  <reference>
    <citation>Martin E, Shapiro JR. Osteogenesis imperfecta:epidemiology and pathophysiology. Curr Osteoporos Rep. 2007 Sep;5(3):91-7. Review.</citation>
    <PMID>17925189</PMID>
  </reference>
  <reference>
    <citation>Miller ME, Hangartner TN. Temporary brittle bone disease: association with decreased fetal movement and osteopenia. Calcif Tissue Int. 1999 Feb;64(2):137-43.</citation>
    <PMID>9914321</PMID>
  </reference>
  <reference>
    <citation>Moore MS, Minch CM, Kruse RW, Harcke HT, Jacobson L, Taylor A. The role of dual energy x-ray absorptiometry in aiding the diagnosis of pediatric osteogenesis imperfecta. Am J Orthop (Belle Mead NJ). 1998 Dec;27(12):797-801.</citation>
    <PMID>9880097</PMID>
  </reference>
  <reference>
    <citation>Roughley PJ, Rauch F, Glorieux FH. Osteogenesis imperfecta--clinical and molecular diversity. Eur Cell Mater. 2003 Jun 30;5:41-7; discussion 47. Review.</citation>
    <PMID>14562271</PMID>
  </reference>
  <reference>
    <citation>Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979 Apr;16(2):101-16.</citation>
    <PMID>458828</PMID>
  </reference>
  <reference>
    <citation>Maioli M, Gnoli M, Boarini M, Tremosini M, Zambrano A, Pedrini E, Mordenti M, Corsini S, D'Eufemia P, Versacci P, Celli M, Sangiorgi L. Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients. Eur J Hum Genet. 2019 Jul;27(7):1090-1100. doi: 10.1038/s41431-019-0373-x. Epub 2019 Mar 18.</citation>
    <PMID>30886339</PMID>
  </reference>
  <reference>
    <citation>Zionts LE, Nash JP, Rude R, Ross T, Stott NS. Bone mineral density in children with mild osteogenesis imperfecta. J Bone Joint Surg Br. 1995 Jan;77(1):143-7.</citation>
    <PMID>7822373</PMID>
  </reference>
  <reference>
    <citation>Hill CL, Baird WO, Walters SJ. Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study. Health Qual Life Outcomes. 2014 Apr 16;12:54. doi: 10.1186/1477-7525-12-54.</citation>
    <PMID>24742068</PMID>
  </reference>
  <reference>
    <citation>Hald JD, Folkestad L, Harsløf T, Brixen K, Langdahl B. Health-Related Quality of Life in Adults with Osteogenesis Imperfecta. Calcif Tissue Int. 2017 Nov;101(5):473-478. doi: 10.1007/s00223-017-0301-4. Epub 2017 Jul 4.</citation>
    <PMID>28676897</PMID>
  </reference>
  <reference>
    <citation>Vanz AP, van de Sande Lee J, Pinheiro B, Zambrano M, Brizola E, da Rocha NS, Schwartz IVD, de Souza Pires MM, Félix TM. Health-related quality of life of children and adolescents with osteogenesis imperfecta: a cross-sectional study using PedsQL™. BMC Pediatr. 2018 Mar 2;18(1):95. doi: 10.1186/s12887-018-1077-z.</citation>
    <PMID>29499676</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2019</study_first_posted>
  <last_update_submitted>October 3, 2019</last_update_submitted>
  <last_update_submitted_qc>October 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Istituto Ortopedico Rizzoli</investigator_affiliation>
    <investigator_full_name>Luca Sangiorgi</investigator_full_name>
    <investigator_title>Head of Medical Genetics Departement and Clinical Bioinformatic Laboratory</investigator_title>
  </responsible_party>
  <keyword>Disease Registry</keyword>
  <keyword>Natural History Study</keyword>
  <keyword>Genotype-Phenotype Correlation</keyword>
  <keyword>Brittle Bone Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

